Skip to main content

Drug Interactions between momelotinib and phenytoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

phenytoin momelotinib

Applies to: phenytoin and momelotinib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with potent CYP450 3A4 inducers may decrease the plasma concentration and therapeutic effects of momelotinib. The proposed mechanism is increased metabolism of momelotinib via the CYP450 3A4 isoenzyme. However, momelotinib is metabolized by multiple pathways and so the clinical significance is unclear. In a phase I study, coadministration of multiple doses of rifampin (600 mg once daily) following a single dose of momelotinib (200 mg) reduced the Cmax and AUC of momelotinib by 29% and 46%, respectively, when compared with a single dose of momelotinib (200 mg) plus a single dose of rifampin (600 mg). No data are available for use with other, less potent inducers.

MANAGEMENT: Caution and monitoring for decreased momelotinib efficacy may be required when used concomitantly with potent CYP450 3A4 inducers. An alternative agent with less potential for induction should be considered if possible.

Drug and food interactions

Moderate

phenytoin food

Applies to: phenytoin

Phenytoin levels may decrease when the suspension is given with enteral feedings. This could lead to a loss of seizure control. You could interrupt the feeding for 2 hours before and after the phenytoin dose. Alternatively, you may give the phenytoin suspension diluted in water and flush the tube with water after administration. These would make it easier for your body to absorb the medication. However, this still may not entirely avoid the interaction and may not always be feasible. You should have your phenytoin levels checked upon starting and stopping of enteral feedings. In addition, using phenytoin together with food may alter the effects of phenytoin. Contact your doctor if you experience worsening of seizure control or symptoms of toxicity, including twitching eye movements, slurred speech, loss of balance, tremor, muscle stiffness or weakness, nausea, vomiting, feeling light-headed, fainting, and slow or shallow breathing. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Ask your doctor before making any changes to your therapy.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.